A new method of wound treatment: targeted therapy of skin wounds with reactive oxygen species-responsive nanoparticles containing SDF-1α

Abstract

Objective To accelerate wound healing through promoting vascularization by using reactive oxygen species (ROS)-responsive nanoparticles loaded with stromal cell-derived factor-1α(SDF-1α). Methods The ROS-reactive nanomaterial poly-(1,4-phenyleneacetone dimethylene thioketal) was synthesized, and its physical and chemical properties were characterized. ROS-responsive nanoparticles containing SDF-1α were prepared through a multiple emulsion solvent evaporation method. The loading capacity, stability, activity of the encapsulated protein, toxicity, and in vivo distribution of these nanoparticles were determined. These nanoparticles were administered by intravenous infusion to mice with full-thickness skin defects to study their effects on the directed chemotaxis of bone marrow mesenchymal stem cells, wound vascularization, and wound healing. Results The synthesized ROS-reactive organic polymer poly-(1,4-phenyleneacetone dimethylene thioketal) possessed a molecular weight of approximately 11.5 kDa with a dispersity of 1.97. ROS-responsive nanoparticles containing SDF-1α were prepared with an average diameter of 110 nm and a drug loading capacity of 1.8%. The encapsulation process showed minimal effects on the activity of SDF-1α, and it could be effectively released from the nanoparticles in the presence of ROS. Encapsulated SDF-1α could exist for a long time in blood. In mice with full-thickness skin defects, SDF-1α was effectively released and targeted to the wounds, thus promoting the chemotaxis of bone marrow mesenchymal stem cells toward the wound and its periphery, inducing wound vascularization, and accelerating wound healing.

Redox regulation in regenerative medicine and tissue engineering: The paradox of oxygen

“…A more elegant approach could be to supplement oxygen delivery with the modulation of endogenous antioxidant systems by designing a scaffold that is responsive to ROS levels (Martin et al, ; Tang et al, ; Figure a). For example, this could be done by using poly(thioketal) urethane or poly‐(1,4‐phenyleneacetone dimethylene thioketal) in tissue engineered scaffolds or nanoparticles for drug delivery in the presence of ROS.…”

A review on Nano-therapeutic drug delivery carriers for effective wound treatment strategies

“…SDF1 -elastin-like-peptide nanoparticles for wound healing α and comprised of SDF1 (stromal cell-derived growth factor-1) and an elastin-like peptide that confered the ability to selfassemble into nanoparticles and resulted that SDF1-ELP fusion protein nanoparticles were promising agents for the treatment of chronic skin wounds (Yeboah et al, 2016). Tang et al (2015), developed a new method of wound treatment that was targeted therapy of skin wounds with reactive oxygen species-responsive nanoparticles containing SDF-1 .And encapsulated SDF-1 α α (stromal cell-derived growth factor-1) could exist for a long time in blood. In mice with full-thickness skin defects, SDF-1 was α effectively released and targeted to the wounds, thus promoting the chemotaxis of bone marrow mesenchymal stem cells toward the wound and its periphery, inducing wound vascularization, and accelerating wound healing.…”

Antimicrobial Nanostructures for Neurodegenerative Infections

“…Nanoparticles and nanomedicines contribute to various pharmaceutical applications, like diagnosis of disease progression, drug delivery, and treatment of various ailments, such as cancer, thrombosis, wounds, osteoporosis, vertebral fracture, and microbial infective diseases, e.g., TB and HIV-associated opportunistic infections (Khajuria et al, 2014;Palekar et al, 2016;Sagar et al, 2015;Tang et al, 2015;Wolfram et al, 2015). Furthermore, it is expected that they will produce potential therapeutic agents for neuroinfective disorders.…”